Brings precision therapies for gynaecological cancers
GSK announced the availability of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialised treatments in cancer care.
Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer, in India. Jemperli works by blocking the PD-1 pathway, a mechanism that cancer cells use to evade immune detection, thereby enabling immune cells to recognise and attack the tumour more effectively.
Jemperli’s efficacy is based on scientific evidence from the GARNET trial in patients with dMMR/MSI-H advanced or recurrent endometrial cancer. The study demonstrated that Jemperli achieved an objective response rate of 45.5 per cent, with an estimated probability of maintained response of 93.3 per cent and 83.7 per cent at 12 and 24 months, respectively. Combined with an acceptable safety profile, these findings highlight the potential for durable clinical benefit in a population where standard chemotherapy has historically offered limited efficacy and poor long-term outcomes.
Bhushan Akshikar, Managing Director, GSK India, said: “The launch of Jemperli and Zejula marks a pivotal moment for GSK in India, as we foray into oncology with a strong focus on innovation-led, high-impact therapies. These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India.”
Dr Shalini Menon, EVP – Medical Affairs, GSK India, said: “Gynaecological cancers represent a growing public health challenge in India, especially among women above the age of 50, and those with obesity and metabolic syndrome. Jemperli introduces immunotherapy into the treatment paradigm for advanced or recurrent endometrial cancer, offering a targeted option for patients with dMMR tumours. Zejula expands access to a convenient, first-line maintenance therapy in advanced ovarian cancer.”
